Full-Time
Updated on 7/21/2026
Develops precision oncology therapeutics and pipelines
$145k - $185k/yr
Boston, MA, USA
In Person
Find people who can refer or advise you
Antares Therapeutics focuses on developing precision oncology medicines. It advances targeted cancer therapies by leveraging Scorpion Therapeutics’ discovery platform acquired by Lilly, using its validated pipeline and leadership with deep oncology experience to guide research and development. The company works by identifying cancer-specific targets and creating therapies that act on those targets, followed by clinical validation and eventual commercialization in advanced cancer indications. Its differentiation comes from access to Scorpion’s discovery capabilities, the support and resources of Lilly, and a leadership team with experience in oncology and life sciences, enabling a science-driven approach to push the boundaries of precision medicine. Antares aims to shape the future of precision oncology by delivering transformative treatments that can improve outcomes for cancer patients.
Company Size
51-200
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$282M
Headquarters
Boston, Massachusetts
Founded
2025
Find people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
– Multi-target collaboration will leverage Antares’ proprietary discovery engine to generate highly selective small molecule medicines against historically undruggable oncology targets –
Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched...
BOSTON, MA, USA I June 10, 2025 I Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing.